Theoretically, the second drug in a combination is expected to kill any of the microbes left alive by the first antibiotic. But the new study demonstrated that when a patient is already tolerant to the first drug, adding a second one spurs resistance by promoting the reproduction of bacteria that were not killed immediately.
…the same evolutionary processes involved in the development of antibiotic tolerance and resistance are likely at play in cancer as well and might be used to inform treatment. Tumor cells might become tolerant of chemotherapy first and then develop resistance and spread it to other drugs.
I don’t understand the premise of this write-up, particularly how it applies to oncology; it does not seem to logically flow from the thesis discussed in #msg-153175785. Comments?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”